Global Commercializing Biomarkers Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Commercializing Biomarkers Market Insights, Forecast to 2034
Biomarkers measure cellular, biochemical or molecular changes in human tissues, cells or fluids, and contribute to future diagnostics and treatment. The development of biomarkers is time consuming and expensive, requiring the involvement of industry from early stages to better direct the research.
Global Commercializing Biomarkers market is expected to reach to US$ 22310 million in 2024, with a positive growth of %, compared with US$ 21390 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Commercializing Biomarkers industry is evaluated to reach US$ 29560 million in 2029. The CAGR will be 4.8% during 2024 to 2029.
Globally, Commercializing Biomarkers key manufacturers include Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia and ALMAC, etc. Roche, Dako (Agilent Technologies), Merck are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Commercializing Biomarkers were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Commercializing Biomarkers market and estimated to attract more attentions from industry insiders and investors.
Commercializing Biomarkers can be divided into Consumables, Services and Software,, etc. Consumables is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Commercializing Biomarkers is widely used in various fields, such as Oncology, Cardiology, Neurology and Others, etc. Oncology provides greatest supports to the Commercializing Biomarkers industry development. In 2022, global % sales of Commercializing Biomarkers went into Oncology filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Commercializing Biomarkers market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Commercializing Biomarkers market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Oncology
Cardiology
Neurology
Others
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Commercializing Biomarkers plant distribution, commercial date of Commercializing Biomarkers, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Commercializing Biomarkers introduction, etc. Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Commercializing Biomarkers
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Commercializing Biomarkers market is expected to reach to US$ 22310 million in 2024, with a positive growth of %, compared with US$ 21390 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Commercializing Biomarkers industry is evaluated to reach US$ 29560 million in 2029. The CAGR will be 4.8% during 2024 to 2029.
Globally, Commercializing Biomarkers key manufacturers include Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia and ALMAC, etc. Roche, Dako (Agilent Technologies), Merck are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Commercializing Biomarkers were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Commercializing Biomarkers market and estimated to attract more attentions from industry insiders and investors.
Commercializing Biomarkers can be divided into Consumables, Services and Software,, etc. Consumables is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Commercializing Biomarkers is widely used in various fields, such as Oncology, Cardiology, Neurology and Others, etc. Oncology provides greatest supports to the Commercializing Biomarkers industry development. In 2022, global % sales of Commercializing Biomarkers went into Oncology filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Commercializing Biomarkers market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Commercializing Biomarkers market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Segment by Application
Oncology
Cardiology
Neurology
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Commercializing Biomarkers plant distribution, commercial date of Commercializing Biomarkers, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Commercializing Biomarkers introduction, etc. Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Commercializing Biomarkers
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices